DanCann Pharma A/S Releases 2024 Annual Report Highlighting Growth and Operational Efficiency
Summary
None As a result, the net financing for 2024 amounted to approximately 6.7 MDKK, while the Companys debt positions were fully reset, leaving it debt-free by the end of the financial year. None The Company successfully continued its strategic transition towards a lean, asset-light model, focusing on sourcing, importing, and distributing cannabinoid-based medicines. None Significant progress in pipeline development, with submissions for multiple new products to the Danish Medicines Agency, and preparations for entry into the OTC segment. None Confirmation of the permanent status of the Danish Pilot Programme for medicinal cannabis, ensuring long-term market stability and validating the therapeutic potential of cannabinoids. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.This disclosure contains information that DanCann Pharma A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014).